Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Summer;14(3):479-484.
doi: 10.22088/cjim.14.3.479.

Interleukine-2 serum level in breast cancer patients

Tutik Harjianti  1 , Andi Fachruddin  1 , Rahmawati Minhajat  1 , Sahyuddin Saleh  1 , Dimas Bayu  1
Affiliations

Interleukine-2 serum level in breast cancer patients

Tutik Harjianti et al. Caspian J Intern Med. 2023 Summer.

Abstract

Background: Breast cancer is a form of cancer that typically affects females. In general, cancer is caused by an imbalance between oncogene and supressor gene factors, including immunity factors against cancer cells. This study aims to compare the levels of IL-2 between breast cancer patients and healthy women, and also compare the levels of IL-2 between HER-2 positive and HER-2 negative, ER/PR positive and ER/PR negative, and among different malignancy grades of breast cancer patients.

Methods: This is an observational study using case control method. We include 46 breast cancer patients and 40 healthy women. Blood samples were taken from 46 breast cancer patients (20 HER-2 negative and 26 HER-2 positive patients); 40 of them received hormonal status (29 ER/PR negative and 11 ER/PR positive patients); and from 46 breast cancer patients, 37 of them were divided into malignancy grade. The level of IL-2 was compared between cases and controls and also among the breast cancer patients with HER-2 negative and positive; ER/PR negative and positive; and breast cancer with low, moderate and high grade.

Results: IL-2 level was higher in breast cancer patients than in controls (9.400 pg/mL and 3.990 pg/mL respectively, P=0.003). IL-2 level is significantly higher in the breast cancer cases with positive HER-2 compared to negative HER-2 expression (11.154pg/mL and 7.120pg/mL respectively, P=0.001. No association between ER/PR expression nor breast cancer grading with IL-2 level.

Conclusion: IL-2 level is higher in breast cancer patients, especially breast cancer patients with HER-2 positive expression.

Keywords: Breast cancer; ER/PR; Grading; HER-2; IL-2..

PubMed Disclaimer

Conflict of interest statement

We have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Difference of IL-2 level in breast cancer patients with positive HER-2 and negative HER-2
See this image and copyright information in PMC

References

    1. Abbas A, Lichtman A, Pillai S. Cellular and molecular immunology. 6th ed. Philadelphia: Elsevier Ltd ; 2007. pp. 389–404.
    1. Abeloff M, Wolf A, Weber B. Clinical oncology. 4th ed. Philadelphia: Elsevier; 2008. Cancer of the breast; pp. 1875–930.
    1. De Boer RJ, Hogeweg P, Dullens HF, De Weger RA, Den Otter W. Macrophage T Lymphocyte Interactions in The Anti-Tumor Immune Response: A Mathematical Model. J Immunol. 1985;134:2748–58. - PubMed
    1. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? J Clin Endocrinol Metab. 2005;16:293–9. - PubMed
    1. Fasoulakis Z, Kolios G, Papamanolis V, Kontomanolis EN. Interleukins associated with breast cancer. Cureus. 2018;10:3549. - PMC - PubMed

LinkOut - more resources